癌症治疗中的免疫检查点抑制剂——我们如何提高临床获益？
Immune Checkpoint Inhibitors in Cancer Therapy-How Can We Improve Clinical Benefits?
作者信息
Baxevanis Constantin N
机构信息
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.
出版信息
Cancers (Basel). 2023 Jan 31;15(3):881. doi: 10.3390/cancers15030881.
Abstract
Immune checkpoint inhibitors (ICIs) are in the spotlight of cancer treatment by increasing the probability for long-term survival in patients with metastatic disease and by considerably prolonging progression-free survival in patients at early disease stages [...].
摘要
免疫检查点抑制剂（ICIs）因提高转移性疾病患者的长期生存概率以及显著延长疾病早期患者的无进展生存期，而成为癌症治疗的焦点[……]。
相似文献
1
Immune Checkpoint Inhibitors in Cancer Therapy-How Can We Improve Clinical Benefits?癌症治疗中的免疫检查点抑制剂——我们如何提高临床获益？
Cancers (Basel). 2023 Jan 31;15(3):881. doi: 10.3390/cancers15030881.
2
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).在完成 2 年免疫检查点抑制剂治疗或在疾病无进展停药后获得持久缓解的晚期和/或转移性非小细胞肺癌患者中的长期结局：多中心真实世界数据（KCSG LU20-11）。
Cancer. 2022 Feb 15;128(4):778-787. doi: 10.1002/cncr.33984. Epub 2021 Oct 27.
3
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.免疫相关不良事件作为免疫检查点抑制剂治疗转移性肾细胞癌患者的临床生物标志物。
Oncologist. 2021 Oct;26(10):e1742-e1750. doi: 10.1002/onco.13868. Epub 2021 Jul 8.
4
Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors.相关驱动基因的生物标志物可预测免疫检查点抑制剂的抗肿瘤疗效。
Front Immunol. 2022 Sep 15;13:995785. doi: 10.3389/fimmu.2022.995785. eCollection 2022.
5
Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.免疫检查点抑制剂联合或不联合放疗用于转移性非小细胞肺癌的疗效与安全性：一项系统评价和荟萃分析
Front Pharmacol. 2023 Jan 24;14:1064227. doi: 10.3389/fphar.2023.1064227. eCollection 2023.
6
Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.二线免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗转移性肾细胞癌患者的疗效：一项真实世界研究。
Immunotherapy. 2022 Apr;14(5):309-320. doi: 10.2217/imt-2021-0108. Epub 2022 Feb 21.
7
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.程序性死亡配体1表达≥50%的转移性非小细胞肺癌一线帕博利珠单抗单药治疗的长期真实世界结局
Front Oncol. 2022 Mar 25;12:834761. doi: 10.3389/fonc.2022.834761. eCollection 2022.
8
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.抗PD-1/PD-L1联合疗法与癌症标准治疗方案的疗效和安全性：一项系统评价与荟萃分析。
Oncoimmunology. 2021 Feb 23;10(1):1878599. doi: 10.1080/2162402X.2021.1878599.
9
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.免疫检查点抑制剂治疗复发和/或转移性头颈部鳞状细胞癌患者的超进展性疾病及其临床影响：韩国癌症研究组HN 18-12
J Cancer Res Clin Oncol. 2020 Dec;146(12):3359-3369. doi: 10.1007/s00432-020-03316-5. Epub 2020 Jul 15.
10
Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.实体器官移植受者转移性癌症患者接受免疫检查点抑制剂治疗的临床结局：单中心分析。
Cancer. 2020 Nov 1;126(21):4780-4787. doi: 10.1002/cncr.33134. Epub 2020 Aug 12.
引用本文的文献
1
Advancing precision medicine: Uncovering biomarkers and strategies to mitigate immune-related adverse events in immune checkpoint inhibitors therapy.推进精准医学：揭示生物标志物及减轻免疫检查点抑制剂治疗中免疫相关不良事件的策略。
Toxicol Rep. 2025 Apr 24;14:102035. doi: 10.1016/j.toxrep.2025.102035. eCollection 2025 Jun.
2
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.下一代免疫疗法：推进癌症治疗的临床应用
J Clin Med. 2024 Oct 30;13(21):6537. doi: 10.3390/jcm13216537.
3
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.AdAPT-001 的 TGF-β 陷阱使肿瘤升温，并降低检查点抑制剂耐药性。
J Immunother Cancer. 2024 Oct 26;12(10):e009613. doi: 10.1136/jitc-2024-009613.
4
Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer.纳武利尤单抗治疗晚期和转移性宫颈癌方案的有效性及结果的系统评价
Diseases. 2024 Apr 15;12(4):77. doi: 10.3390/diseases12040077.
5
Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.免疫检查点抑制剂相关心肌炎：病例报告及文献复习。
Medicina (Kaunas). 2024 Jan 28;60(2):224. doi: 10.3390/medicina60020224.
6
Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review.免疫治疗相关心肌炎患者再挑战的耐受性：病例报告及文献复习。
Medicina (Kaunas). 2023 Nov 3;59(11):1946. doi: 10.3390/medicina59111946.
7
Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy.基于金属的纳米颗粒作为局部癌症免疫疗法佐剂的应用前景。
Pharmaceutics. 2023 Apr 27;15(5):1346. doi: 10.3390/pharmaceutics15051346.
本文引用的文献
1
Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone.联合使用S-腺苷甲硫氨酸和免疫检查点抑制剂靶向治疗管腔B型乳腺癌可减少原发性肿瘤的生长、进展以及向肺和骨的转移。
Cancers (Basel). 2022 Dec 22;15(1):48. doi: 10.3390/cancers15010048.
2
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.大疱性类天疱疮作为免疫检查点抑制剂不良反应的单机构回顾性研究经验
Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.
3
Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.上皮性卵巢癌中的肿瘤浸润淋巴细胞（TILs）：异质性、预后影响及与免疫检查点的关系
Cancers (Basel). 2022 Oct 29;14(21):5332. doi: 10.3390/cancers14215332.
4
Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers.癌症治疗中的检查点抑制剂：对头颈部癌症的临床益处
Cancers (Basel). 2022 Oct 11;14(20):4985. doi: 10.3390/cancers14204985.
5
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot.溶瘤腺病毒：对抗癌症的冷战终于升温。
Cancers (Basel). 2022 Sep 27;14(19):4701. doi: 10.3390/cancers14194701.
6
Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications.免疫疗法在胃癌治疗中的应用：分子与临床意义
Cancers (Basel). 2022 Sep 8;14(18):4378. doi: 10.3390/cancers14184378.
7
Radiomic Signatures Associated with CD8 Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study.与CD8肿瘤浸润淋巴细胞相关的影像组学特征：一项系统评价和质量评估研究
Cancers (Basel). 2022 Jul 27;14(15):3656. doi: 10.3390/cancers14153656.
8
Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance?癌症治疗中的免疫检查点抑制剂——如何克服耐药性？
Cancers (Basel). 2022 Jul 22;14(15):3575. doi: 10.3390/cancers14153575.
9
Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer.综合基因组分析揭示头颈部癌免疫治疗反应中的临床关联。
Cancers (Basel). 2022 Jul 18;14(14):3476. doi: 10.3390/cancers14143476.
10
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?在真实世界临床实践中，将雷莫西尤单抗添加到多西他赛中的疗效与免疫检查点抑制剂治疗史有关吗？
Cancers (Basel). 2022 Jun 16;14(12):2970. doi: 10.3390/cancers14122970.
Zotero 插件